Related by context. All words. (Click for frequent words.) 88 Awarded Patent 85 Files Patent Application 83 Patent Issued 82 Announce License Agreement 82 Files Patent 81 Announces FDA Clearance 81 Achieves Milestone 80 Introduces Breakthrough 80 Announces Issuance 80 Launches Next Generation 80 Sign Licensing Agreement 80 Introduces Next Generation 80 Shows Promise 79 Commercializes 79 Introduces Revolutionary 79 Announces License Agreement 79 Signs Licensing Agreement 79 Announce Collaboration 79 Announces Licensing Agreement 79 Announces Successful Completion 79 Receives FDA Clearance 79 Announces Immediate Availability 78 Sign License Agreement 78 Receives Notice 78 Attains 78 Announces Initiation 78 Files IND 78 Achieves Significant 78 Introduces Innovative 78 FDA Clears 78 Finalizes Acquisition 78 Develop Next Generation 78 Develops Innovative 78 Reports Positive 78 Unveils Innovative 78 Submits Application 78 Announce Availability 78 Introduces Enhanced 77 Strengthens Its 77 Acquires Exclusive 77 Announce Collaboration Agreement 77 Signs License Agreement 77 Jointly Announce 77 Launches Innovative 77 Completes Successful 77 Announces Termination 77 Secures Financing 77 Strengthens Position 77 Begins Shipment 77 Receives Orphan Drug Designation 77 Completes Enrollment 77 Launches Enhanced 77 Obtains Patent 77 Announce Licensing Agreement 77 Expands Portfolio 77 Unveils Revolutionary 77 Delivers Next Generation 77 Announces Expanded 77 Releases Next Generation 77 Enters Agreement 77 Issued Patent 77 Subsidiary Enters 77 Initiates Clinical Trial 77 Patent Covering 76 Acquires Assets 76 Receives Certification 76 Significantly Improves 76 Secures Funding 76 Discontinues 76 Receives Favorable 76 Develop Novel 76 Receives Regulatory 76 Achieves ISO #:# Certification [002] 76 Obtains Exclusive License 76 Announces Receipt 76 Completes Divestiture 76 Subsidiary Receives 76 Announces Acquisition 76 Expands Capabilities 76 Fortifies 76 Significantly Increases 76 Expand Collaboration 76 Enters Into Agreement 76 Successfully Completes 76 Awarded Patents 76 Unveils Next Generation 76 Completes Patient Enrollment 76 Secures Additional 76 Signs Agreements 76 Completes Installation 76 Announces Publication 76 Announces Availability 75 Validates 75 Announces Formation 75 Announces Commencement 75 Announce Merger Agreement 75 Significantly Reduces 75 Expands Distribution 75 Further Strengthens 75 Provides Update Regarding 75 Completes Integration 75 Finalizes Agreement 75 Provides Updates 75 Launches Unique 75 Acquire Assets 75 Receives Approval 75 Expand Relationship 75 Settle Patent Litigation 75 Announces Launch 75 Unveils Latest 75 Announces Definitive Agreement 75 Licenses Novel 75 Reduces Risk 75 Closes Acquisition 75 Expands Capacity 75 Announce Completion 75 Subsidiary Acquires 75 Broadens Its 75 Subsidiary Signs 75 Gets FDA Clearance 75 Unveils Newest 75 Announces Favorable 75 Introduces Expanded 75 Expands Availability 75 Presents Preclinical Data 75 Announces Enhancements 75 Secures Patent 75 Revolutionizes 75 Closes Sale 75 Introduces Novel 75 Formalizes 75 Provides Comprehensive 74 Terminates Contract 74 Extends Reach 74 Receives Positive 74 Announce Receipt 74 Present Preclinical Data 74 Begins Shipping 74 Successfully Completed 74 Spins Off 74 Acquirer Company 74 Receives Milestone Payment 74 Receives Notification 74 Enrolls First 74 Jumps Higher 74 Receives NASDAQ 74 Obtains Approval 74 Expands Presence 74 Patents Covering 74 Completes Acquisition 74 Presents Positive 74 Enters Into Exclusive 74 Initiates Phase II 74 Receives Order 74 Furthers 74 Completes Merger 74 Receives Commitment 74 Regains Compliance 74 Awarded Multi 74 Awarded Prestigious 74 Announces Addition 74 Inks Licensing Deal 74 Announces Signing 74 Updates Shareholders 74 Announces Expansion 74 Jointly Develop 74 Enter Into 74 Announces Additions 74 Q2 Loss Narrows 74 Unveils Breakthrough 74 Acquires Controlling Interest 74 Completes Purchase 74 Receives Prestigious 74 Enters Into License Agreement 74 Completes Acquisitions 74 & Sullivan Recognizes 74 Announces Successful 74 Settles Litigation 74 Announces Positive 74 Announce Exclusive 74 Showcases Innovative 74 Completes Initial 74 Provide Comprehensive 74 Obtains 74 Successfully Closes 74 Significantly Expands 74 Completes Tender Offer 73 Receives Funding 73 Commercialize 73 Introduces Unique 73 Announces Effective Date 73 Submits NDA 73 Obtains License 73 Platform Enables 73 Q3 Loss Widens 73 Continues Momentum 73 Complete Merger 73 Files Patent Infringement 73 Receives CE Marking 73 Completes Reverse Merger 73 Announces Divestiture 73 Strengthens Leadership 73 Finalizes Purchase 73 Achieves Record 73 Inks Pact 73 Initiates Enrollment 73 Completes Financing 73 Q3 Loss Narrows 73 Receives SFDA Approval 73 Board Authorizes 73 Unveils Expanded 73 Amends Agreement 73 Completes Sale 73 Unveils Groundbreaking 73 Releases Latest 73 Achieves Record Sales 73 Dramatically Increases 73 Provides Preliminary 73 Announces Filing 73 Announces Dismissal 73 Provides Guidance 73 Settle Patent Dispute 73 Streamlines Operations 73 Reconfirms 73 Expands Reach 73 Changes Name 73 Announces Revised 73 Announces Preliminary 73 Renews Agreement 73 Announce Settlement 73 Offers Affordable 73 Other OTC MNDP 73 Announces Completion 73 Spins Out 73 Receives Recognition 73 Completes Transition 73 Q2 Loss Widens 73 Introduces Powerful 73 Wins Patent Infringement 73 Files Provisional 73 Signs Distribution 73 Reaches Milestone 73 Reduces Debt 73 Achieves Certification 73 Announce Agreement 73 Restructures Debt 73 Penetrates 73 Expands Scope 73 DayTradersDigest.com Profiles 73 Successfully Concludes 73 Announce Interoperability 73 Paves Way 73 Successfully Tests 73 Rebrands 73 Announces Presentation 73 Receives Conditional 73 Releases Enhanced 73 Secures Contract 73 Enters Into Strategic 73 Successfully Tested 73 Q1 Loss Narrows 73 Reports Receipt 73 Announce Expanded 73 Enters Strategic 73 Appoints Experienced 72 Shareholders Approve Acquisition 72 Receives Favorable Ruling 72 Regains Compliance With 72 Q1 Loss Widens 72 Updates Status 72 Announces Organizational Changes 72 Settles Patent Litigation 72 Aquires 72 Files Shelf Registration Statement 72 Demonstrate Innovative 72 Wins Contract 72 Secures 72 Differentiates 72 Successfully Demonstrates 72 Launches Redesigned Website 72 Initiates Dosing 72 Confirms Receipt 72 Signs Definitive Agreement 72 Demonstrates Significant 72 FDA Approves 72 Scientists Develop 72 Delivers Breakthrough 72 Unveils Enhanced 72 Receives Orphan Drug 72 Dramatically Expands 72 Announces Shareholder Approval 72 Executes Agreement 72 FDA Okays 72 Expands Into 72 Receives Confirmation 72 Strengthens Balance Sheet 72 Boosts Productivity 72 Patent Infringement Lawsuit Against 72 Ink Deal 72 Extends Collaboration 72 Taglich Brothers Initiates Coverage 72 Expands Internationally 72 Helps Reduce 72 Announces Proposed 72 Q4 Loss Narrows 72 Confirms Commitment 72 Awarded GSA Schedule 72 Initiates Clinical Trials 72 Proves Successful 72 Closes Acquisition Of 72 Signs Reseller Agreement 72 Restructures Operations 72 Unveils Powerful 72 Secures Long Term 72 Enters Joint Venture 72 Provides Shareholder 72 Increases Ownership 72 Q4 Loss Widens 72 Flagship Product 72 Collaborates With 72 Broadens 72 Announces Intent 72 Amplifies 72 Signs Pact 72 Study Demonstrates 72 Forges Partnership 72 Demonstrates Commitment 72 Report Examines 72 Repositions 72 Launches Groundbreaking 72 Enters Into Licensing Agreement 72 Completes Purchase Of 72 Study Identifies 72 Demonstrates Potential 72 Holds Promise 72 Strengthens Commitment 72 Improves Efficiency 72 Gets Approval 72 Named Exclusive Distributor 72 Ships #th 72 Doubles Capacity 72 Receives Clearance 72 Develops Breakthrough 72 Expands Functionality 72 Taro Receives 72 Offers Unique 72 Achieves Prestigious 72 Develops Novel 72 Enters Into 72 Announce Joint Venture 72 Sinks Lower 72 Submits 72 Drug Candidate 71 Signs Merger Agreement 71 Completes Merger With 71 Monetizes 71 Reinforces 71 Forges Ahead 71 Signs MOU 71 Eliminates Need 71 Delivers Enhanced 71 Wins Approval 71 Delivers Comprehensive 71 TheWallStreetLeader.com Profiles 71 Announces Departure 71 Awarded GSA 71 Rated Speculative Buy 71 Achieves ISO # 71 Consummates 71 Completes Expansion 71 Accelerates 71 Researchers Develop 71 Announces Stockholder Approval 71 Releases Latest Version 71 Signs Option Agreement 71 Wins Prestigious 71 Successfully Launches 71 Continues Aggressive 71 Builds Momentum 71 Enters Negotiations 71 Taps Into 71 Announces Early Termination 71 Accelerates Growth 71 Updates Guidance 71 Provides Unprecedented 71 Announces Closing 71 Finalizes 71 Improves Quality 71 Receives Approvable Letter 71 Continues Expansion 71 Successfully Integrates 71 Initiates Clinical 71 Receives CE 71 Officially Launches 71 Quadruples 71 Expands Relationship With 71 Hits Milestone 71 CybeRelease Decliners 71 Moves Towards 71 Report Analyzes 71 Inc. OTCBB MNDP 71 Outlines Strategy 71 Licenses Patents 71 Procures 71 Signs LOI 71 Completes Private Placement 71 Collaborators Present 71 Regains Full 71 Announces 71 Study Indicates 71 Extend Partnership 71 Wins Coveted 71 Increases Capacity 71 Seeks Approval 71 Launches Website 71 Inks Deal With 71 Announces Cancellation 71 Bodes Well 71 Successfully Deploys 71 Extends Capabilities 71 More Than Doubles 71 Signs Long Term 71 Debuts Next Generation 71 Dutton Associates Announces 71 Granted Orphan Drug 71 Acquires Majority 71 Patent Infringement Lawsuit 71 Celebrates Decade 71 Exercises Option 71 Dramatically Reduces 71 Revitalizes 71 Protects Against 71 Awarded Contract 71 Introduces 71 Explore Strategic Alternatives 71 Improves Customer 71 Signs Definitive 71 Finalizes Sale 71 Enters Into Definitive Agreement 71 Helps Prevent 71 Offers Unprecedented 71 Appoints Seasoned 71 Patent Dispute 71 Presents Positive Preclinical 71 Files Registration Statement 71 Latest Addition 71 Reacquires 71 Successfully Complete 71 Launches Breakthrough 71 Sign Definitive Agreement 71 Subsidiary Enters Into 71 Acquires 71 Reaffirms Commitment 71 Signs Exclusive 71 Therapeutic Competitors Companies 71 Could Revolutionize 71 Submits IND 71 Announces Ticker Symbol 71 StockSource.us Reports 71 Solidifies 70 Magazine Recognizes 70 Cuts Costs 70 Identifies Potential 70 Regains NASDAQ 70 Improves Survival 70 Study Confirms 70 Announce Strategic 70 Further Validates 70 Submits Biologics License Application 70 Named Finalist 70 Re Affirms 70 Immunomedics Announces 70 Achieves Highest 70 Completes 70 Completes Dosing 70 Expert Joins 70 Receives Authorization 70 Annouces 70 Signs Agreement 70 Mutually Agree 70 Thewallstreetleader.com Profiles 70 Submits Supplemental 70 Signs Lease 70 Reports Profitable 70 Awarded Qualifying Therapeutic 70 Announces Stock Repurchase 70 Subsidiary Awarded 70 Diversifies 70 Announces Sponsorship 70 Receives Notice From 70 Receives Coveted 70 FDA Accepts 70 Closes Financing 70 Obtains FDA 70 Inks Distribution 70 Being Studied 70 Recieves 70 Renegotiates 70 Strengthens Presence 70 Nears Completion 70 Proven Effective 70 Leading Provider 70 Achieves Record Revenue 70 Announce Licensing 70 Extends Leadership 70 Completes Asset 70 Terminates Agreement 70 Refocuses 70 Establish Joint Venture 70 Expands Offerings 70 Resubmits 70 Announces Rebranding 70 Doubles Size 70 Extends Tender Offer 70 AnaSpec Introduces 70 Increases Efficiency 70 Enters Into Joint Venture 70 Receives 70 Settles Patent Dispute 70 Gains Momentum 70 Enhances User Experience 70 Announces Definitive Agreements 70 Temporarily Suspends 70 Snaps Up 70 & Sullivan Lauds 70 Extends Commitment 70 Demonstrates Interoperability 70 Manufacturer Selects 70 Collaborators Publish 70 Receives Unsolicited 70 Announces Granting 70 Expands Deployment 70 Receives Fast Track 70 Achieves Positive 70 Achieves Breakthrough 70 Net Loss Widens 70 Concludes Successful 70 Winning Streak Continues 70 Momentum Continues 70 Exclusive License 70 PRODUCT SOURCE 70 Solution Enables 70 Announce Breakthrough 70 Provides Updated 70 Ranked Number 70 Develop Innovative 70 Positions Itself 70 Expands Relationship 70 Provide Enhanced 70 Buys Majority Stake 70 Issues Guidance 70 Sees Continued 70 Announces Reseller Agreement 70 Announce Commencement 70 Introduces Groundbreaking 70 Demonstrates Positive 70 CRWESelect CRWESelect.com Highlights 70 Delivers Powerful 70 Issues Statement Regarding 70 News Unternehmensnachrichten 70 Reinvents 70 Bolsters 70 Earns Prestigious 70 Reveals Positive 70 Wins Prestigious Award 70 Migrates 70 Successfully Completes Tender Offer 70 BioSante Pharmaceuticals Announces 70 Shares Surge 70 Shows Promising 70 Announces Private Placement 70 Posts Strong 70 Announce Formation 70 Stockholders Approve Acquisition 70 Enters Into Letter 70 Certifies 70 Settle Litigation 70 Receives Prestigious Award 70 Earns Coveted 70 Win Prestigious 70 Restructures 70 Extends Maturity 70 Significantly Enhances 70 Announce Partnership 70 Earns Milestone Payment 70 Host Webinar 70 Posts Record 70 Obtains Exclusive 70 Closes Private Placement 70 Announces Consummation 70 Submits Proposal 70 Completes Conversion 70 Announce Successful Completion 70 Patents Issued 70 Pending Acquisition 70 Sharpens Focus 70 Helps Identify 70 Announces Upcoming 70 Commences Operations 70 Expands 70 Subsidiary Expands 70 Moves Headquarters 70 Distinguishes 70 Unlocks 70 Unifies 69 Announces Expiration 69 Ramps Up Production 69 Sees Significant 69 Offers Enhanced 69 Preclinical Data 69 Announce Definitive Agreement 69 Deliver Integrated 69 Demonstrates Next Generation 69 Commences 69 Provides Clarification 69 Reports Preclinical Data 69 Receives ISO #:# [001] 69 Expands Commitment 69 Inks Agreement 69 Reduces Costs 69 Expand Presence 69 Terminates 69 Continues Rapid 69 Extend Relationship 69 Completes Recapitalization 69 Announce Launch 69 Study Validates 69 Announces Postponement 69 Expands Coverage 69 Net Loss Narrows 69 Speeds Up 69 Completes Previously Announced 69 Retains Leading 69 Initiates Phase III 69 Announces Adjournment 69 Dramatically Improves 69 Announces Favorable Ruling 69 Achieves ISO 69 Celebrates Opening 69 Closes Previously Announced 69 Non Invasive 69 Forms Strategic 69 Earnings Postmortem 69 Updates Outlooks 69 Deloitte commends 69 Shares Soar 69 Awarded Contracts 69 Patent Infringement 69 FDA Approvals 69 Announces Intention 69 Achieves Profitability 69 Exploring Strategic Alternatives 69 Helps Predict 69 Receives Tentative Approval 69 Subsidiary Wins 69 Shareholders Approve Merger 69 Introduces Affordable 69 Announces Resumption 69 Initiates Phase 69 Launches Expanded 69 Named Fastest Growing 69 Reaches Agreement 69 Signs Joint Venture 69 Expands Footprint 69 Accepted Into 69 Subsidiary Completes 69 Announce Reseller Agreement 69 Voluntarily Withdraw 69 Rolls Out 69 Signs Contract 69 Expands Globally 69 Expands Scientific Advisory 69 Results Confirm 69 Provides Update 69 Acquire Controlling Interest 69 Licensing Deal 69 Patent Lawsuit 69 Receives Initial 69 Solution Delivers 69 Accelerate Commercialization 69 Aligns 69 Delivers Improved 69 Files Lawsuit Against 69 Beefs Up 69 Realigns 69 Deliver Powerful 69 Motorola Invests 69 Study Proves 69 Helps Improve 69 AllPennyStocks.com Spotlights 69 Initiates Voluntary Recall 69 Marks Milestone 69 Improves Productivity 69 Announces Non Brokered 69 Increases Productivity 69 Successfully Demonstrate 69 Addresses Growing 69 Successfully Completes Phase 69 Stockholders Approve Merger 69 Wins Summary Judgment 69 Successfully Completes Acquisition 69 Helps Ensure 69 Demonstrates Innovative 69 Buy Privately Held 69 Closes Second Tranche 69 Withdraws Application 69 Welcomes Analyst Initiation 69 Proudly Announces 69 Report Indicates 69 Starts Shipping 69 Elevates 69 OTCStockExchange.com Stock Alert 69 Patent Infringement Litigation 69 Sign Reseller Agreement 69 Files Petition 69 Gets Favorable Ruling 69 Develops Next Generation 69 Novartis Novo Nordisk 69 Finalize Agreement 69 Completes Refinancing 69 Announces Affiliation 69 Completes Sale Of 69 Achieves SAS 69 Showcases Next Generation 69 Ink Pact 69 Makes Strides 69 Authorizes Additional 69 Propels 69 Receives Conditional Approval 69 Extend Collaboration 69 Inks Deal 69 Moves Into 69 Introduces Newest 69 Meets Primary Endpoint 69 Attains Gold Certified Partner 69 Jointly Launch 69 Announces Tentative Approval 69 Files Voluntary 69 Announces Underwriters Exercise 69 Expedites 69 High Growth Forecasted 69 Deliver Presentation 69 Retains Investor Relations 69 Stockholders Approve 69 Announces Resignation 69 Sees Continued Growth 69 Opens Door 68 Showcases Latest 68 Extends Relationship 68 Supercharges 68 Announces Appointment 68 Reduces Cost 68 Launches 68 Complies With 68 Progresses 68 Furthers Commitment 68 Successfully Implements 68 Deliver Next Generation 68 FY# Loss Widens 68 Awarded Contract Extension 68 Improves Outcomes 68 Toshiba Develops 68 Board Unanimously Rejects 68 Announce Merger 68 Regains Nasdaq 68 Continues Steady 68 Fifth Consecutive Year 68 Markets Examine 68 Receives Approval From 68 Named Cool Vendor 68 Receive Milestone Payment 68 Associatesfortune.com 68 Gains Ground 68 Settle Patent 68 Closes Buyout 68 Announces Refinancing 68 Milestone Achieved 68 Enters Definitive Agreement 68 Resolves Dispute 68 Earns Certification 68 Announce Signing 68 Present Webinar 68 Proves Effective 68 Leaps Ahead 68 Daytradersdigest.com Profiles 68 Extends Expiration Date 68 Increases Stake 68 Earns Top 68 Acquires Remaining Interest 68 Clears Path 68 Announce Early Termination 68 Outperforms 68 Extends Offer 68 MONSTERSTOX.COM Monsterstox.com 68 Jointly Offer 68 Enhances Customer 68 Reinforces Commitment 68 Celebrates Successful 68 Clinical Trial Results 68 Tumor Targeting 68 otcstockexchange.com 68 Continues Commitment 68 Effectively Treats 68 Acquire Majority 68 Assets Acquirer Company 68 Pursues 68 Shareholder Opinions 68 Prolongs 68 Reports Third Consecutive 68 Voluntarily Withdraws 68 Confirms Filing 68 Confirms Significant 68 Announce Initiation 68 Trend Continues Down 68 Forges Strategic 68 Significantly Expand 68 Completes Reorganization 68 Extends Contract 68 Retains CCG Investor Relations 68 Maintains Strong 68 Scientists Uncover 68 Settles Dispute 68 Demonstrates Improved 68 Achieves Cisco 68 4Q Loss Widens 68 Signs Purchase Agreement 68 Enters Exclusive 68 Achieves Record Growth 68 Receives Approvals 68 Renews Commitment 68 Study Examines 68 IND Application 68 Ventures Invests 68 Remains Committed 68 Commences Tender Offer 68 Announces Share Repurchase 68 Commences Phase 68 Unveils 68 Demonstrates Long Term 68 Teledyne Acquires 68 Renews Contract 68 Receives ISO #:# [002] 68 Emphasizes Importance 68 Scientists Identify 68 Announces Discontinuation 68 Announces Proposed Acquisition 68 Unveils Latest Version 68 Shares Plummet 68 Merger Creates 68 Solidifies Position 68 Enables Faster 68 Capitalizes 68 Reaches Settlement 68 Delivers Unprecedented 68 Reaches Settlement Agreement 68 Chooses 68 Empowers Consumers 68 Media NewsEdge STOCK MARKETING 68 Redefines 68 Discloses 68 Settles Patent Suit 68 Unsolicited Proposal From 68 Intros 68 Licensing Pact 68 Shareholders Approve 68 Significant Increase 68 Earns Recognition 68 Widely Used 68 Reshapes 68 Guides Inline 68 Successful Completion 68 Technicals Showing Bullish 68 IrelandRESEARCH AND MARKETS 68 Files Patent Infringement Lawsuit 68 Inc. LATEST NEWS 68 Report Initiates Independent 68 Identifies Key 68 Announces Latest Version 68 Sells Shares 68 NEC Develops 68 Delivers Unparalleled 68 Expand Into 68 Deploys 68 Patent Broadly Covering 68 Reach Settlement 68 Provides Detailed 68 Small Molecule 68 Expand Capacity 68 Announces Stock Buyback 68 Fast Growing 68 Deepens 68 Previews Earnings 68 AGREEMENTS SOURCE 68 Announces Restatement 68 Relaunches 68 HSR Waiting Period 68 Underpins 68 Bullish Engulfing Pattern 68 Clarifies Status 68 Closes Merger 68 Enlarges 68 Signs Memorandum 68 Gains Traction 68 Multi Billion Dollar 68 Moves Forward 68 Acquire Privately Held 68 Q2 Profit Rises 68 Posts Quarterly 68 Shares Climb 68 Deliver Innovative 68 Successfully Delivers 67 Successfully Defends 67 Molecular Diagnostic Test 67 Renames 67 Files Suit Against 67 Shareholders Approve Name 67 Signs Letter 67 Anounces 67 Receives Accreditation 67 Initiate Clinical Trial 67 Inks Deals 67 Combats 67 Fourth Consecutive 67 Directors Authorizes 67 Sees Strong 67 Daytradersdigest.com 67 Acquisition Strengthens 67 Releases Version 67 Enters Into Agreements 67 Software Simplifies 67 Files Patents 67 Adopts Shareholder Rights 67 Finalizes Contract 67 Enables Rapid 67 Initiates 67 Bearish Speculation 67 Scoops Up 67 Activity Alert 67 Presents Webinar 67 Attracting Bullish Investors 67 Bullish Speculation 67 Alert Technicals Showing Bullish 67 Completes Buyout 67 Protects Customers 67 Announces Spin Off 67 Researchers Identify 67 Settles Patent Infringement Lawsuit 67 Terminates Merger Agreement 67 Heightens 67 Distribution Pact 67 Stock Soars 67 Options Activity 67 Exclusive Distributor 67 Alert Technicals Showing Bearish 67 Acquires Majority Stake 67 Sets Stage 67 Reach Settlement Agreement 67 TRADESHOW SOURCE 67 Q4 Profit Surges 67 Shows Promise Against 67 Deliver Comprehensive 67 Reduces Size 67 Extends Deadline 67 Inhibits 67 Zacks Analyst Blog Highlights 67 Makes Debut 67 Enters Into Collaboration 67 Demonstrates Latest 67 Rapidly Growing 67 Announces Keynote Speakers 67 Announces Repurchase 67 www.otc advisors.com names 67 Amends Terms 67 Establishes Strategic 67 Delivers Innovative 67 MARKETING AGREEMENTS SOURCE 67 Demonstrates Ability 67 Revises Fourth Quarter 67 Surpasses 67 Subscribes 67 Prove Effective 67 Refines 67 Prescribes 67 Abandons Plans 67 Canaccord Genuity Reiterates Buy 67 Renews Partnership 67 Commences Cash 67 Study Reveals 67 Patent Lawsuit Against 67 Reduces Pain 67 Commences Production 67 Completes Transaction 67 CONFERENCE CALLS SOURCE 67 Enables Easy 67 Website Launched 67 Completes Deployment 67 Begins Dosing 67 Confirms Validity 67 Underscores Commitment